UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
 
                             Washington, D.C. 20549
 
                                  SCHEDULE 13D
 
                   Under the Securities Exchange Act of 1934
                               (Amendment No. 7)*
 
                              THE COOPER COMPANIES, INC.
                                (NAME OF ISSUER)
 
                     COMMON STOCK, PAR VALUE $.10 PER SHARE
                         (TITLE OF CLASS OF SECURITIES)
 
                                    216648105
                                 (CUSIP NUMBER)
 
                           HAROLD L. SCHNEIDER, ESQ.
                             TENZER GREENBLATT LLP
         405 LEXINGTON AVENUE, NEW YORK, NEW YORK 10174 (212) 573-4348
 (NAME ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO RECEIVE NOTICE AND
                                COMMUNICATIONS)
 
                               FEBRUARY 28, 1995
            (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)
 
If  the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the  subject of this Schedule  13D, and is filing  this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
 
Check the following box if a fee is being paid with the statement [ ]. (A fee is
not required only if the reporting person): (1) has a previous statement on file
reporting  beneficial  ownership  of more  than  five  percent of  the  class of
securities described  in Item  1;  and (2)  has  filed no  amendment  subsequent
thereto  reporting beneficial ownership of five  percent or less of such class.)
(See Rule 13d-7).
 
NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule  13d-1(a) for other  parties to whom  copies are to  be
sent.
 
*  The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for   any   subsequent  amendment   containing  information  which  would  alter
disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed
to be 'filed' for the  purpose of Section 18 of  the Securities Exchange Act  of
1934  ('Act') or otherwise subject to liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).




                                  SCHEDULE 13D
 
CUSIP NO. 216648105                                            PAGE 2 OF 4 PAGES
 
            
- -----------------------------------------------------------------------------------------------------------
1              NAME OF REPORTING PERSON
               S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
               Cooper Life Sciences, Inc.
               94-2563513
- -----------------------------------------------------------------------------------------------------------
2              CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
                                                                 (b) [ ]
- -----------------------------------------------------------------------------------------------------------
3              SEC USE ONLY
- -----------------------------------------------------------------------------------------------------------
4              SOURCE OF FUNDS*
               Not Applicable
- -----------------------------------------------------------------------------------------------------------
5              CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)  [ ]
- -----------------------------------------------------------------------------------------------------------
6              CITIZENSHIP OR PLACE OF ORGANIZATION
               Delaware
- -----------------------------------------------------------------------------------------------------------
               7      SOLE VOTING POWER
                      6,967,600 shares of Common Stock
  NUMBER OF    -------------------------------------------------------------------------------------------
   SHARES      8      SHARED VOTING POWER
BENEFICIALLY
  OWNED BY            -0-
    EACH       -------------------------------------------------------------------------------------------
  REPORTING    9      SOLE DISPOSITIVE POWER
   PERSON
    WITH              6,967,600 shares of Common Stock
               -------------------------------------------------------------------------------------------
               10    SHARED DISPOSITIVE POWER
                      -0-
- -----------------------------------------------------------------------------------------------------------
11             AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
               6,967,600 shares of Common Stock
- -----------------------------------------------------------------------------------------------------------
12             CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*                   [ ]
- -----------------------------------------------------------------------------------------------------------
13             PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
               20.04%
- -----------------------------------------------------------------------------------------------------------
14             TYPE OF REPORTING PERSON*
               CO
- -----------------------------------------------------------------------------------------------------------


 
                     *SEE INSTRUCTIONS BEFORE FILLING OUT!


     This  Amendment No.  7 amends  and supplements Item  5 of  the Schedule 13D
filed with the Securities and Exchange  Commission on June 22, 1992, as  amended
by  Amendment No. 1 dated November 12, 1992, Amendment No. 2 dated July 6, 1993,
Amendment No. 3  dated August 24,  1993, Amendment  No. 4 dated  July 14,  1994,
Amendment  No. 5 dated August  15, 1994, and Amendment  No. 6 dated September 6,
1994 (as amended, the 'Schedule 13D'), by Cooper Life Sciences, Inc., a Delaware
corporation ('CLS'), relating to the Common Stock, par value $.10 per share (the
'Common Stock')  of The  Cooper  Companies, Inc.,  a Delaware  corporation  (the
'Company').  Except  as  modified  hereby,  there  has  been  no  change  in the
information previously reported in the Schedule 13D.
 
ITEM 5. INTEREST IN SECURITIES OF ISSUER.
 
     The number of shares of Common Stock which may be deemed to be beneficially
owned by CLS has decreased by more than 1% of the number of shares of the  class
which  are  deemed  to  be  outstanding. Said  decrease  is  the  result  of the
utilization by CLS of 500,000 shares of  Common Stock as part of the price  paid
by  it  to purchase  newly issued  shares  of Unistar  Gaming Corp.,  a Delaware
corporation.



                                Page 3 of 4 Pages

 

                                   SIGNATURE
 
     After reasonable inquiry,  and to the  best of my  knowledge and belief,  I
certify  that the information set forth in  this statement is true, complete and
correct.
 
                                          COOPER LIFE SCIENCES, INC.
 
                                          By:        /S/ STEVEN ROSENBERG
                                               .................................
                                                       VICE PRESIDENT
 
            March 7, 1995
 .....................................
                 DATE


                                Page 4 of 4 Pages